Frank Milton Balis, M.D.

faculty photo
Professor of Pediatrics at the Children's Hospital of Philadelphia
The Louis and Amelia Canuso Family Endowed Chair for Clinical Research in Oncology, The Children's Hospital of Philadelphia Philadelphia, PA
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
Office: 267-426-5414
Fax: 267-425-5839
B.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Solid tumors in children, renal tumors in children, clinical pharmacology of anticancer drugs

Description of Other Expertise

Clinical research infrastructure and informatics

Description of Research Expertise

Clinical pharmacology of anticancer drugs, cancer biomarkers, clinical trial design

Selected Publications

Busch CM and Balis FM: Age-dependent reference intervals in children for the disialoganglioside, G(D2), a circulating tumor biomarker for the childhood cancer, neuroblastoma. Clin Biochem 101: 1-4, 2022.

Moon JK, Hwang R, Balis FM, Mattei P: An enhanced recovery after surgery protocol in children who undergo nephrectomy for Wilms tumor safely shortens hospital stay. J Pediatr Surg In Press, 2022.

Fox E, Busch C, DeBernardo A, Segers B, Gottschalk J, Womer R, Balamuth N, Bagatell R, Balis F.: A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. Cancer Chemother Pharmacol 87: 807-815, Jun 2021.

Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP.: Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res lin Cancer Res, 2021.

Balis F, Green DM, Anderson C, Cook S, Dhillon J, Gow K, Hiniker S, Jasty-Rao R, Lin C, Lovvorn H, MacEwan I, Martinez-Agosto J, Mullen E, Murphy ES, Ranalli M, Rhee D, Rokitka D, Tracy EL, Vern-Gross T, Walsh MF, Walz A, Wickiser J, Zapala M, Berardi RA, Hughes M: Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19: 945-977, 2021.

Balis FM, McCully CL, Busch CM, Fox E, Warren KE.: Pharmacokinetics of the disialoganglioside, G D2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. J Circ Biomark 10: 26-29, 2021.

Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K, Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ.: Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol 86: 829-840, Dec 2020.

Fox E, Blaney SM, Moreno L, Norris R, Skolnik JM, Adamson PC, Balis FM. : General principles of chemotherapy. Principles and Practice of Pediatric Oncology 8th Ed. Pizzo PA and Poplack DG (eds.). 2020.

Balis FM, Busch CM, Desai AV, Hibbitts E, Naranjo A, Bagatell R, Irwin M, Fox E. : The ganglioside, GD2, as a circulating tumor biomarker for Neuroblastoma. Pediatic Blood & Cancer Oct 2019.

Adamson Peter C, Veal Gareth J, Womer Richard B, Meany Holly J, Bernhardt M Brooke, Frazier A Lindsay, Balis Frank M: Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function. Pediatric Blood & Cancer 66(6): e27672, Jun 2019.

back to top
Last updated: 06/17/2022
The Trustees of the University of Pennsylvania